Post-transplant lymphoproliferative disease in children following solid organ transplant and rituximab - The final answer?

Pediatric Transplantation

Volumn 11, Issue 6, 2007, Pages 575-577

  Gross, Thomas G ^a  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; RITUXIMAB;

ANTIVIRAL THERAPY; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CELL PROLIFERATION; CELLULAR IMMUNITY; COST EFFECTIVENESS ANALYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; EDITORIAL; EPSTEIN BARR VIRUS; GRAFT INFECTION; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; ORGAN TRANSPLANTATION; SURVIVAL TIME; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

ANTIBODIES, MONOCLONAL; CHILD; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOPROLIFERATIVE DISORDERS; ORGAN TRANSPLANTATION;

EID: 34547408268     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2007.00748.x     Document Type: Editorial

References (21)

1. Webber SA, Naftel DC, Fricker FJ, et al. Lymphoproliferative disorders after heart transplantation: A multi-institutional study. Lancet 2006 : 367 : 233 239.
2. Ho M, Jaffe R, Miller G, et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988 : 45 : 719 727.
3. van Esser JWJ, Niesters HGM, van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002 : 99 : 4361 4369.
4. Greenfield HM, Gharib MI, Turner AJL, et al. The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: Can it successfully predict outcome and guide intervention? Pediatr Blood Cancer 2006 : 47 : 200 205.
5. McDiarmid SV, Jordan S, Lee GS, et al. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998 : 66 : 1604 1611.
6. Lee TC, Savoldo B, Rooney CM, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transpl 2005 : 5 : 2222 2228.
7. Smets F, Latinne D, Bazin H, et al. Ratio between Epstein-Barr virus viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 2002 : 73 : 1603 1610.
8. Lee TC, Goss JA, Rooney CM, et al. Quantification of a low cellular immune response at aid in identification of pediatric liver transplant recipients at high-risk for EBV infection. Clin Transplant 2006 : 20 : 689 694.
9. Aull MJ BJ, Trofe J, First MR, et al. Experience with 274 cardiac transplant recipients with post-transplant lymphoproliferative disorder: A report from the Israel Penn International Transplant Tumor Registry. Transplantation 2004 : 78 : 1676 1682.
10. Hayashi RJ, Kraus MD, Patel AL, et al. Posttransplant lymphoproliferative disease in children: Correlation of histology to clinical behavior. J Pediatr Hematol Oncol 2001 : 23 : 14 18.
11. Buell JF, Gross TG, Hanaway MJ, et al. Chemotherapy for PTLD: The Israel Penn International Transplant Tumor Registry Experience. Transplant Proc 2005 : 37 : 956 957.
12. Gross TG, Bucuvalas J, Park J, et al. Low dose chemotherapy for the treatment of refractory post-transplant lymphoproliferative disease in children. J Clin Oncol 2005 : 23 : 6481 6488.
13. Benkerrou M, Jais JP, Leblond V, et al. Anti-B-cell monoclonal antibody treatment of severe post-transplant B-lymphocyte disorder: Prognostic factors and long-term outcome. Blood 1998 : 92 : 3137 3147.
14. Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody, history and mechanism of action. Am J Transpl 2006 : 6 : 859 866.
15. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: Results of a prospective multi-center phase 2 study. Blood 2006 : 107 : 3053 3057.
16. Oertel SHK, Verschuuren E, Reinke P, et al. Effect of anti-CD20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transpl 2005 : 5 : 2901 2906.
17. Hayashida M, Ogita K, Matsuura T, et al. Successful prolonged rituximab treatment for post-transplant lymphoproliferative disorder following donor liver transplantation in a child. Pediatr Transplant 2007 : 11 : 671 675.
18. Yang J, Tao Q, Flinn IW, et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: Disappearance after rituximab therapy does not predict clinical response. Blood 2000 : 96 : 4055 4063.
19. Rhodes MM, Delbeke D, Whitlock JA, et al. Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma. J Pediatr Hematol Oncol 2006 : 28 : 300 306.
20. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: Summary of Society for Hematopathology Workshop. Semin Diagn Pathol 1997 : 14 : 8 14.
21. Chadburn A, Cesarman E, Liu YF, et al. Molecular genetic analysis demonstrates that multiple posttransplantation lymphoproliferative disorders occurring in one anatomic site in a single patient represent distinct primary lymphoid neoplasms. Cancer 1995 : 75 : 2747 2756.